NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Seer, Inc. (SEER) Stock Analysis

Seer, Inc. (SEER) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

SEER

$1.95

+$0.01 (+0.52%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SEER with… →

SEER Key Statistics

As of Sep 4, 2026
Trading
Open
$1.93
Previous Close
$1.94
Day's Range
1.93–1.96
52-Week Range
1.55–2.41
Volume
68.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.51
Valuation
Market Cap
$107.98M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
7.59
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.22
Financials (FY)
Revenue (FY)
$16.12M+15.57%
Net Income (FY)
−$73.60M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
55.37M
1-Year Return
−2.99%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
1.07M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SEER Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+6.56%
2025−20.78%
2024+19.07%
2023−66.55%
2022−74.57%
2021−59.37%
2020 (partial year)−0.57%

As of September 4, 2026.

SEER Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$16.12M−$73.60M−456.6%
2024$13.95M−$86.60M−620.9%
2023$15.18M−$86.28M−568.3%
2022$14.69M−$92.97M−633.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$16.12M$8.01M−$77.99M−$73.60M−456.6%
2024$13.95M$6.83M−$100.10M−$86.60M−620.9%
2023$15.18M$7.03M−$103.46M−$86.28M−568.3%
2022$14.69M$6.29M−$97.24M−$92.97M−633.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SEER Valuation vs Biotechnology Median

Median of 656 stocks
MetricSEERBiotechnology medianvs median
P/S ratio7.5915.2650% below
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Seer, Inc. (SEER) is capitalised at $107.98M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 124.

Over the past 52 weeks the price has ranged from $1.55 to $2.41. The most recent close on file for SEER is $1.95, dated September 4, 2026. That is +$0.01 (+0.52%) against the previous close. The latest close sits 25.81% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $16.12M. Against the prior fiscal year total of $13.95M, that is a change of +15.57%. The same year closed with a net loss of $73.60M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −1.22.

Across the 4 fiscal years on file, revenue moves from $14.69M in 2022 to $16.12M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 7.59. On price-to-sales that is 50.24% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned −2.99%. Measured over 5 years, that is −46.33% a year compounded. Beta against the wider market is reported at 1.51. Annualized volatility over the trailing 5 years is 74.42%.

Growth & Income

The record shows no dividend for SEER.

2026 is still running; the price is +6.56% year to date. The strongest complete calendar year on file is 2024 at +19.07%; the weakest is 2022 at −74.57%. Of the 5 complete calendar years on file, 1 finished higher.

Peer Comparison

Seer, Inc. (SEER) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Seer, Inc. SEER $107.98M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Seer, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Seer, Inc.

Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Visit website →